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Background: Adverse events from intrapartum antibiotic prophylaxis (IAP) are poorly documented yet essential
to inform clinical practice for neonatal group B Streptococcus (GBS) disease prevention. In this systematic review,
we appraised and synthesised the evidence on the adverse events of IAP in the mother and/or her child.
Methods: We searched MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Cochrane, and
Science Citation Index from date of inception until October 16th 2016. Reference lists of included studies and
relevant systematic reviews were hand-searched. We included primary studies in English that reported any adverse
events from intrapartum antibiotics for any prophylactic purpose compared to controls. The search was not
restricted to prophylaxis for GBS but excluded women with symptoms of infection or undergoing caesarean
section. Two reviewers assessed the methodological quality of studies, using the Cochrane Risk of Bias tool, and the
Risk of Bias Assessment Tool for Nonrandomised Studies. Results were synthesised narratively and displayed in text
and tables.
Results: From 2364 unique records, 30 studies were included. Despite a wide range of adverse events
reported in 17 observational studies and 13 randomised controlled trials (RCTs), the evidence was inconsistent
and at high risk of bias. Only one RCT investigated the long-term effects of IAP reporting potentially serious
outcomes such as cerebral palsy; however, it had limited applicability and unclear biological plausibility.
Seven observational studies showed that IAP for maternal GBS colonisation alters the infant microbiome.
However, study populations were not followed through to clinical outcomes, therefore clinical significance is
unknown. There was also observational evidence for increased antimicrobial resistance, however studies were
at high or unclear risk of bias.
Conclusions: The evidence base to determine the frequency of adverse events from intrapartum antibiotic
prophylaxis for neonatal GBS disease prevention is limited. As RCTs may not be possible, large, better quality,
and longitudinal observational studies across countries with widespread IAP could fill this gap.
Trial registration: CRD42016037195.
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Group B Streptococcus (GBS), or Streptococcus agalactiae,
a gram-positive bacterium, is the leading cause of mortal-
ity and morbidity from neonatal sepsis [1]. GBS colonises
the gastrointestinal and/or genitourinary tract in 10 to
30% of pregnant women [2–4], with a recent global rate of
17.9% [5]. If a pregnant woman is vaginally colonised with
GBS when she is in labour, there is a 36% chance that
GBS will be transmitted to her neonate [6]. Most GBS
colonised neonates will be asymptomatic, however less
than 1% may suffer from invasive early-onset GBS disease
(less than seven days, EOGBS) [7]. Globally, culture-
confirmed EOGBS has an estimated incidence of 0.43 per
1000 live births and a case fatality rate of 12.1%, which
may be an underestimate [8].
To prevent EOGBS, the currently available preven-
tion is intrapartum antibiotic prophylaxis (IAP), ad-
ministered to mothers identified at risk of vertically
transmitting GBS bacteria [9, 10]. The current
recommendation for IAP in Western Europe, North
America, and Australasia is intravenous penicillin (or
ampicillin) given as soon as possible after the onset
of labour and then every four hours until delivery,
with intravenous cefazolin in the US, or clindamycin
in the UK, for mothers allergic to penicillin [9–11].
Pregnant women are selected to be offered IAP using
different policies. In some countries, women are of-
fered IAP if they present with known risk factors for
GBS, such as intrapartum fever or GBS bacteriuria,
and in many other countries, women are actively
screened for GBS colonisation at 35-37 weeks of
pregnancy and treated in labour if they are positive
[12]. Screening for GBS maternal colonisation is con-
troversial as up to 30% of women with positive re-
sults at 35-37 weeks revert to negative by labour [13],
and the large majority of women who are colonised
with GBS during labour have healthy neonates who
will not suffer from EOGBS.
A number of potential harms have been suggested as a
result of the widespread use of IAP associated with neo-
natal GBS prevention [14, 15, 10]. IAP has been associated
with antimicrobial resistance [16–18], neonatal infections
caused by gram-negative bacteria [19, 15, 18], Clostridium
difficile infection in mothers [20], maternal anaphylaxis,
which although very rare, can be fatal for mother and baby
[9], neonatal microbiota changes that could lead to short
and long-term health problems [21–23], anxiety for the
mother, family, and medical staff, and the medicalisation
of labour [15, 10].
The potential harms from IAP are poorly docu-
mented and understood, and there has been no sys-
tematic review of the evidence. This information is
essential to assess whether the benefits of IAP treat-
ment for neonatal GBS disease prevention outweighthe harms. Therefore, we conducted a systematic re-
view to identify, appraise, and synthesise the evidence
on the adverse events experienced by the mother
and/or her child after receiving IAP treatment. This
review was conducted as part of a national review on
whether the UK should introduce a GBS screening
programme, a crucial part of these screening reviews
is to understand the harms of treatment.Methods
This systematic review is reported according to PRISMA
guidelines [24]. As this was a secondary analysis of exist-
ing data, ethical consent was not required.Search strategy
Searches were conducted in MEDLINE, MEDLINE In-
Process & Other Non-Indexed Citations, EMBASE,
Cochrane Library: Cochrane Database of Systematic
Reviews, CENTRAL, DARE and HTA databases, and
Science Citation Index Expanded from date of inception
until October 16th 2016. The search strategy combined
both text words and MeSH terms for antibiotic prophy-
laxis, labour, and adverse events, and was limited to
English and humans (see Additional file 1 for complete
search strategy). We used recommended search filters
for adverse events [25, 26], and systematically
included terms for known IAP adverse events from
previous studies [14, 15, 27, 10] and expert opinion.
We also hand-searched reference lists of included
studies and relevant systematic reviews, and experts
cross-checked included studies.Eligibility criteria and study selection
Two reviewers independently screened the titles, abstracts,
and full texts of all identified records. Disagreements were
resolved by discussion, with involvement of a third reviewer
if necessary. We included any full text randomised con-
trolled trials (RCTs), cohort studies, or case-control studies
in English, reporting any adverse events experienced by
mothers and/or their children after being exposed to antibi-
otics during labour for any prophylactic purpose, compared
to an unexposed control group. As the evidence base on
IAP for neonatal GBS disease prevention is limited, we
included studies on IAP for any prophylactic indication.
IAP studies for caesarean sections or symptomatic mothers,
those in which women were given antibiotics before labour,
or neonates given antibiotics after birth were excluded.
Studies were included if 90% or more of the study
population met the inclusion criteria, or if results for those
who met the inclusion criteria were reported separately.
We excluded case series, case reports, abstracts, editorials,
letters, books, consensus statements, opinions, and reviews.
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Two reviewers independently appraised the risk of bias for
each included study using the Cochrane Risk of Bias (RoB)
tool [28], and the Risk of Bias Assessment Tool for
Nonrandomised Studies (RoBANS) [29]. Selection, per-
formance, detection, attrition, and reporting biases were
assessed and classified as low, high, and unclear risk of bias.
Data extraction and synthesis
Meta-analyses could not be performed due to the hetero-
geneity across the adverse outcomes assessed. Narrative
syntheses were conducted, and the results of individual
studies displayed in text and tables. Missing statistical pa-
rameters of importance were calculated if data permitted.
Odds ratios (ORs) were calculated for case-control studies
and risk ratios (RRs) and risk differences (RDs) were calcu-
lated for all other study designs using Stata version 13
(Stata Corp, College Station, Texas).
Results
Characterisation of included studies
Our search identified 2364 unique references. After
sifting titles and abstracts, 262 full texts were
screened, of which 30 studies met the inclusion cri-
teria and were included in the synthesis (see Fig. 1 for
study flow and Additional file 1 for full text studies ex-
cluded with reason) [30–59]. Fourteen were cohort studies
[30, 32, 33, 46, 35–37, 39, 42, 44, 45, 56, 31, 57], three case-
control [34, 38, 54], 12 RCTs [40, 47–53, 55, 43, 41, 58],
and one a sub-study [59] of an included RCT [58]. Nine
studies investigated IAP for GBS prevention [30, 34, 46, 35,
36, 39, 54, 31, 57], two for GBS prevention and other indi-
cations [37, 42], three for post-partum infection prevention
[40, 49, 50], eight for preterm labour [41, 43, 47, 48, 51–53,
55], two for neonatal sepsis prevention [58, 59], and six did
not state the indication (see Additional file 1: Table S1 for
study characteristics) [32, 33, 38, 45, 44, 56]. Some IAP ef-
fectiveness trials reported outcomes, such as neonatal and
maternal infection, that could plausibly increase from IAP
due to changes in the organisms causing infections and/or
antibiotic susceptibility [18, 44], but could also decrease if
the IAP is successful [40, 43, 47–53, 55, 58]. To prevent
bias in reporting, we reported these outcomes irrespective
of whether they were identified as benefits or harms (see
bottom of Additional file 1: Table S1).
Methodological quality
None of the RCTs were judged as low risk of bias
across all domains as assessed by the Cochrane Risk
of Bias tool (see Fig. 2) [28]. The greatest risk of bias
was in selective outcome reporting, where eight RCTs
were at high risk partly or solely because the
definition and measurement of side effects was not
pre-specified in the methods but only reported in theresults [47–50, 53, 55, 40, 59]. More than half of the
RCTs were rated as having unclear risk of bias for in-
complete outcome data as there was substantial miss-
ing data, for example, on adverse events in the
control group [40, 49–51, 53, 58, 55]. We noted a
number of other sources of bias across RCTs, includ-
ing relatively small sample sizes [41, 52, 59], data not
presented [41, 49, 50], a lack of information on treat-
ment regimens [48] and details of intention to treat
analysis [51, 55], inaccuracies in the numbers pro-
vided for participant flow [53], and parent-reported
outcomes rather than objective assessment [41].
There were no observational studies judged as low risk of
bias across all domains on the RoBANS tool (see Fig. 3)
[29]. The confounding variables domain had the highest
concern, as four studies were rated as high risk [30, 37, 44,
46], none as low risk, and 13 as unclear risk of bias [32–36,
38, 39, 42, 45, 54, 56, 31, 57], as some variables were
accounted for in the study design or at least reported, while
others, such as maternal risk factors, prenatal antibiotics,
and caesarean sections, were not. Likewise, selection of
participants was also unclear across nine studies [32, 33, 39,
44, 45, 54, 56, 31, 57], as there was no mention of how par-
ticipants were selected and/or some important baseline
characteristics were not reported.
Adverse events associated with IAP
A range of child and maternal adverse events were investi-
gated for association with IAP including maternal thrush,
childhood atopic dermatitis, neonatal infections and re-
spiratory distress, necrotising enterocolitis, and Clostridium
difficile bowel problems (see Additional file 1: Table S1 for
summary of results). Below we present the findings on
three key results – gut microbiota, antibiotic resistance,
and long-term adverse events.
Gut microbiota
Seven cohort studies consistently showed that IAP alters
the infant microbiome [30, 32, 33, 36, 39, 31, 57]. At day
2, 3, 6-7, 10, 30, and 90, there were differences in the
relative composition and the colony forming units per
gram (log CFU/g) of organisms in the gut of infants
whose mothers were and were not treated with IAP (see
Tables 1 and 2 for results) [32, 33, 39, 31, 57, 36]. Two
studies also reported on sample richness and biodiver-
sity, finding that at day 6-7 and day 30, infants whose
mothers were treated with IAP had a less diverse micro-
bial profile compared to controls [31, 57]. At day 6-7,
there was also a clear segregation between the micro-
biota profiles of IAP compared to control infants when
they were plotted on principal coordinate analysis plots,
which disappeared by day 30 [31, 57]. Similar to gut
microbiota, Keski-Nisula et al. (2013), [42] found a de-
creased transmission of vaginal Lactobacillus-dominant
Fig. 2 Risk of bias in randomised controlled trials according to the Cochrane RoB [28]
Fig. 1 Flow diagram of study selection
Seedat et al. BMC Pregnancy and Childbirth  (2017) 17:247 Page 4 of 14
Fig. 3 Risk of bias in non-randomised studies according to RoBANS [29]
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were treated with IAP compared to those who were not
(1 versus 13, OR = 0.08 95% CI 0.007–0.80). While there
was consistent evidence on gut microbiota alterations, it
is unclear if any of the alterations are related to clinical
adverse events or not.
Antimicrobial resistance
Six studies reported antimicrobial resistance. Of the RCTs,
Gordon et al. (1995) reported zero cases of multi-resistant
bacterial infections in the intervention group of 58 infants
whose mothers were treated with IAP for preterm labour
[48]. Roca et al. (2016) investigated GBS, Staphylococcus
aureus (S. aureus), and Streptococcus pneumoniae (S.
pneumoniae) resistant to azithromycin in 829 mothers
and 843 infants treated with azithromycin for neonatal
sepsis prevention [58]. S. aureus resistant to azithromycin
were found at day 3 in maternal breast milk, at day 6 in
newborn nasopharynx and maternal breast milk, at day 8
in vaginal swabs, and at day 14 and day 28 in newborn
and maternal nasopharynx and maternal breast milk. S.
pneumoniae resistant to azithromycin were also identified
in the maternal nasopharynx, which occurred at day 28
only (see Additional file 1: Table S1).
Of the four observational studies, Glasgow et al. (2005)
found that in 62 infants whose mothers were treated with
various IAP drugs (indication not stated), 24 (39%) had
ampicillin-resistant organisms, compared to 13/120 (11%)
infants whose mothers were not treated (OR = 5.7 95% CI
2.3-14.3) [38]. The authors also reported a significant dif-
ference when analysing ampicillin-resistant bacteria caus-
ing urinary tract infections separately (OR = 4.3 95% CI
1.6-11.7). Similarly, Stoll et al. (2002) found that mothers
of infants with ampicillin-resistant strains of Escherichia
coli (E. coli) were more likely to have received intrapartumampicillin than those with ampicillin-sensitive strains (26
of 28 [93%] versus 1 of 5 [20%] p = 0.01) [44]. It was un-
clear whether the infants in these two studies were treated
with antibiotics before they were tested for antimicrobial
resistance. Ashkenazi-Hoffnung et al. (2011) did not find
any differences between 17 infants born to mothers
treated with IAP for GBS prevention and 178 infants who
were not, in first generation cephalosporin resistance in E.
coli (60% versus 22.7% p = 0.21) or any bacteria causing
late-onset serious bacterial infections (57% versus 26%
p = 0.19), or ampicillin resistance in E. coli (100% versus
54.5% p = 0.14) or any bacteria causing late-onset serious
bacterial infections (85% versus 63% p = 0.19) [34]. The
authors did find higher development of first gener-
ation cephalosporin-resistant urinary tract infections
(75% versus 23.5% p = 0.04). Lastly, Jaureguy et al.
(2004) did not find a difference in the number of in-
fants colonised with amoxicillin-resistant Enterobac-
teriaceae (10/25 [40%] versus 12/25 [48%], calculated
RR = 0.83 95% CI 0.44-1.56) and amoxicillin-
resistant E. coli (6/25 [24%] versus 11/25 [44%] cal-
culated RR = 0.55 95% CI 0.24-1.25) in the gut of
infants whose mothers were or were not treated with
IAP [39].
Long-term adverse events
Kenyon et al. (2008) was the only RCT that reported on
the long-term adverse events of IAP [41]. They found
that IAP may be associated with severe consequences of
functional impairment and cerebral palsy, as well as
bowel problems in a factorial randomised trial comparing
children aged seven whose mothers had received any
erythromycin (erythromycin alone or combined with
amoxicillin-clavulanate) compared to no erythromycin, and
any amoxicillin-clavulanate (alone or with erythromycin)
Table 1 Qualitative gut microbiota composition of IAP-treated and untreated infants
Organism Study Number of
infants (n) in
each group
Relative abundance in microbiota composition (%) or number of infants (n) colonised
Day 1 Day 2 Day 3 Day 6/ 7 Day 10 Day 30
Phyla
All Arboleya 2016
[33]
IAP n = 14
Control n = 13
No
differences
Actinobacteria Aloisio 2016
[31]a
IAP n = 10
Control
n = 10
IAP: 0.4%
Control: 3.8%
p < 0.05
Arboleya 2016
[33]
IAP n = 14
Control
n = 13
Lower % in IAP,
p < 0.05
Mazzola 2016
[57]a
Breast-fed IAP
n = 7
Breast-fed
Control n = 7
IAP: 0%
Control: 17%
p < 0.001
Mixed-fed IAP
n = 6
Mixed-fed
Control
n = 6
IAP: 1%
Control: 8%
RR 0.13
(CI 0.02-0.98)
IAP: 7%
Bacteriodetes Aloisio 2016
[31]a
IAP n = 10
Control
n = 10
IAP: 16%
Control:
47.7%
p < 0.05
Mazzola 2016
[57]a
Mixed-fed IAP
n = 6
Mixed-fed
Control n = 6
IAP: 21%
Control: 36%
RR 0.59
(CI 0.3 –0.93)
IAP: 34%
Control: 26%
RR 1.31 (CI 0.85-2.01)
Proteobacteria Aloisio 2016
[31]a
IAP n = 10
Control n = 10
IAP: 54.7%
Control:
15.5%
p < 0.05
Arboleya 2016
[33]
IAP n = 14
Control n = 13
Higher % in IAP,
p < 0.001
Mazzola 2016
[57]a
Breast-fed IAP n = 7
Breast-fed
Control n = 7
Higher %
in IAP,
p < 0.062
Mixed-fed IAP
n = 6
Mixed-fed
Control n = 6
IAP: 37%
Control: 17%
RR 2.18
(CI 1.32-3.60)
IAP: 28%
Firmicutes Arboleya 2016
[33]
IAP n = 14
Control n = 13
Lower % in IAP,
p < 0.01
Mazzola 2016
[57]a
Mixed-fed IAP
n = 6
Mixed-fed
Control n = 6
IAP: 41%
Control: 29%
RR 1.14
(CI 0.96-2.08)
IAP: 30%
Family
Bifidobacteriaceae Aloisio 2016
[31]a
IAP n = 10
Control n = 10
IAP: 0.02%
Control:
6.47%
p < 0.05
Arboleya 2015
[32]
IAP n = 14
Control n = 13
Lower % in IAP,
p < 0.05
Comamonadaceae Arboleya 2015
[32]
IAP n = 14
Control n = 13
Lower % in IAP,
p < 0.05
Enterobacteriaceae IAP n = 14
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Table 1 Qualitative gut microbiota composition of IAP-treated and untreated infants (Continued)
Arboleya 2015
[32]
Control n = 13 Higher % in IAP,
p < 0.05
Mazzola 2016
[57]a
Breast-fed IAP n = 7
Breast-fed
Control n = 7
Higher %
in IAP,
p = 0.044
IAP: 44%
Control: 16%
RR 2.75 (CI 1.67-4.54)
Mixed-fed IAP n = 6
Mixed-fed
Control n = 6
IAP: 35%
Control: 17%
RR 2.06
(CI 1.24-3.42)
IAP: 28%
Jaureguy 2004
[39]a
IAP n = 25
Control n = 25
IAP n = 13
Control
n = 16
p = 0.58
IAP: 0%
Lachnospiraceae Mazzola 2016
[57]a
IAP n = 14
Control n = 13
IAP: 4%
Leuconostaceae Arboleya 2015
[32]
IAP n = 14
Control n = 13
Lower % in
IAP, p < 0.05
Micrococcaceae Arboleya 2015
[32]
IAP n = 14
Control n = 13
Lower % in
IAP, p < 0.05
Propionibacteriaceae Arboleya 2015
[32]
IAP n = 14
Control n = 13
Lower % in
IAP, p < 0.05
Staphylococcaceae Arboleya 2015
[32]
IAP n = 14
Control n = 13
Lower % in IAP,
p < 0.05
Streptococcaceae Arboleya 2015
[32]
IAP n = 14
Control n = 13
Lower % in IAP,
p < 0.05
Veillonellaceae Mazzola 2016
[57]a
Breast-fed IAP n = 7
Breast-fed
Control n = 7
Lower % in IAP,
p = 0.035
Unclassified
Actinobacteria
Arboleya 2015
[32]
IAP n = 14
Control n = 13
Lower % in IAP,
p < 0.05
Unclassified Bacilli IAP n = 14
Control n = 13
Lower % in IAP,
p < 0.05
Unclassified
Lactobacillales
IAP n = 14
Control n = 13
Lower % in IAP,
p < 0.05
Genera
Bacteroides Jaureguy 2004
[39]a
IAP n = 25
Control n = 25
IAP n = 13
Control
n = 7
p = 0.15
Mazzola 2016
[57]a
Breast-fed IAP n = 7
Breast-fed
Control n = 7
IAP: 7%
Control: 20%
p = 0.078
Mixed-fed IAP n = 6
Mixed-fed
Control n = 6
IAP: 13%
Control: 32%
RR 0.41
(CI 0.23-0.73)
Bifidobacteria Jaureguy 2004
[39]a
IAP n = 25
Control n = 25
IAP n = 6
Control
n = 12
p = 0.18
Mazzola 2016
[57]a
Breast-fed IAP n = 7
Breast-fed
Control n = 7
IAP: 0%
Control: 16%
p = 0.001
IAP: 6% (compared
to day 7, p = 0.025)
Control: 6%
Mazzola 2016
[57]a
Mixed-fed IAP n = 6
Mixed-fed
Control n = 6
IAP: 1% or 0%
Control: 5%
IAP: 6% (compared
to day 7, p = 0.013)
Control: 19%
RR: 0.32 (CI 0.13-0.76)
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Clostridia Jaureguy 2004
[39]a
IAP n = 25
Control n = 25
IAP n = 3
Control
n = 10
p = 0.04
Enterococci Jaureguy 2004
[39]a
IAP n = 25
Control n = 25
IAP n = 15
Control
n = 17
p = 0.73
Escherichia Mazzola 2016
[57]a
Breast-fed IAP n = 7
Breast-fed
Control n = 7
IAP: 52%
Control: 14%
RR 3.71
(CI 2.21-6.25)
Staphylococci Jaureguy 2004
[39]a
IAP n = 25
Control n = 25
IAP n = 21
Control
n = 22
p = 1.00
Streptococci Mazzola 2016
[57]a
Mixed-fed IAP n = 6
Mixed-fed
Control n = 6
IAP: 32%
Control: 10%
RR 3.2
(CI 1.66-6.15)
IAP: 8% (compared
to day 7, p = 0.042)
Other microbial
genus
Aloisio 2016
[31]a
IAP n = 10
Control n = 10
No significant
differences
CI confidence interval, IAP intrapartum antibiotic prophylaxis, p probability value, RR risk ratio
Numbers in italics calculated by reviewers
aGroup B Streptococcus prophylaxis
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The risk of cerebral palsy was higher in infants whose
mothers received any erythromycin versus no erythromycin
(placebo or amoxicillin-clavulanate) (53/1611 [3%] and 27/
1562 [2%] OR = 1.93 95% CI 1.21-3.09) or any amoxicillin-
clavulanate versus no amoxicillin-clavulanate (placebo or
erythromycin) (50/1587 [3%] and 30/1586 [2%] OR = 1.69
95% CI 1.07–2.67). More children who developed cerebral
palsy had been born to mothers who had received both
antibiotics (35/735) than to mothers who received erythro-
mycin only (18/785), amoxicillin-clavulanate only (15/763),
or double placebo (12/735) (both drugs versus double pla-
cebo: OR = 2.91 95% CI 1.50–5.65). The authors also found
that any erythromycin significantly increased the risk of
bowel problems (64/1611 [4%] versus 38/1562 [2%]
OR = 1.66 95% CI 1.10-2.49) and functional impairment
(658/1554 [42%] versus 574/1498 [38%] OR = 1.18 95% CI
1.02–1.37) compared to no erythromycin. None of these
effects were found for either erythromycin or amoxicillin-
clavulanate alone compared to placebo, however this may
have been a result of insufficient power.
The study had a low risk of bias in all major
domains, however there were critical limitations.
Multiple statistical comparisons were conducted on a
relatively small sample size increasing the probability
of getting a significant effect due to chance. In
addition to cerebral palsy, functional impairment, and
bowel problems, the authors also investigated
diabetes, behavioural problems, educational attain-
ment, attention deficit hyperactivity disorder, andother developmental problems, and did not find any
significant differences between any of the treatment
and control groups. This is particularly important as
the biological plausibility of IAP increasing the risk of
cerebral palsy is unknown.
Discussion
In this systematic review, we presented the evidence on
adverse events experienced by the mother and/or her
child after treatment with intrapartum antibiotic prophy-
laxis (IAP). Despite a wide range of adverse outcomes
reported from 17 observational studies and 13 RCTs,
there was limited high quality information to determine
the frequency of adverse events from IAP for neonatal
GBS disease prevention. The evidence contains much
uncertainty, with a substantial evidence gap around the
long-term effects of IAP. The only RCT investigating the
long-term effects of IAP reported a moderate effect of
severe consequences such as cerebral palsy. This trial
had limited applicability as it used a different drug, a
longer drug regimen, and pre-term rather than term
labour compared to IAP for GBS prevention. We also
found consistent observational evidence that IAP for
neonatal GBS prevention alters the infant microbiome,
with some studies showing changes up to 90 days of life.
However, these study populations were not followed
through to clinical outcomes, therefore the short- and
long-term clinical significance of the changes are
unknown. Finally, there was evidence for increased
antibiotic resistance in some, but not all studies, with no
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dence was at high or unclear risk of bias due to con-
founding variables.
Our review is the first systematic assessment of the
literature on the adverse events from IAP. We had an
extensive search with no date limit, and referencing
checking of all included papers and relevant system-
atic reviews. We also had expert input, two reviewers
conducting processes, including quality appraisal
using validated tools, and we calculated summary
measures for study outcomes where they were not
available. However, as our search was broad and
focused heavily on harms or adverse events search
terms, we may not have found studies which investi-
gated an outcome that would potentially be an
adverse event, but may not have been indexed as
such. Furthermore, as we only included studies for
which full texts were available in English, adverse
events reported in other languages may have been
missed. We were also unable to conduct any meta-
analyses due to the heterogeneity across the adverse
events investigated.
Previous literature has suggested that initial bacterial
colonisation of the gut plays an important role in the
development of the mucosal immune system of infants
[21–23, 42]. Microbiota changes from antibiotics have
been associated with respiratory problems in children
such as asthma, metabolic problems such as obesity and
diabetes, and autism [21–23]. For example, Cox et al.
(2014) demonstrated that low dose penicillin delivered
after birth caused gut microbiota changes that led to per-
manent abnormalities in metabolism and immunity in
mice [60]. More recently, antibiotic exposure before six
months of age or repeatedly during infancy was associated
with increased body mass and height in healthy children
[23]. The antibiotics in these studies were not adminis-
tered intrapartum. Long-term follow-up investigations
linking antibiotic prophylaxis specifically during labour
and early microbiota alterations to clinical consequences
are required to understand their significance.
Evidence on the increase of antibiotic resistance after
IAP was inconsistent. Literature on the trends of antibiotic
resistance in countries offering IAP for neonatal GBS
prevention has shown an increase in rates overtime.
Resistance to clindamycin and erythromycin has increased
in the last 20 years [9], with reported resistance to
erythromycin at 30% or higher in the US and Switzerland,
and above 15% for clindamycin in the US, Switzerland,
and England [61–63]. Similarly, although GBS remains
almost universally susceptible to penicillin [16], in 2005 in
the US, 0.2% of GBS isolates had reached the upper level
of susceptibility [61, 64]. However, these trends are diffi-
cult to attribute specifically to IAP for GBS prevention,
and could be due to other factors.Kenyon et al.’s (2008) RCT had a low risk of bias and
showed that IAP was associated with an increase in the
severe consequences such as cerebral palsy [41].
However, the effect size was small, and with multiple
statistical comparisons conducted on the same population,
the probability of a chance result is increased. Based on
previous literature the plausible biological mechanisms
through which IAP may cause the development of
cerebral palsy are unknown [41, 65]. Complicating these
findings, a second trial on IAP for pregnant women with
preterm rupture of the membranes (excluded due to signs
of infection confounding IAP effects) found no differ-
ence in the proportion of children with cerebral palsy
between treated or untreated women [66]. Therefore,
why cerebral palsy occurred in the first study and
whether it would occur as a result of use of IAP for
neonatal GBS prevention, which involves different
drug regimens and durations, is uncertain.
A Cochrane meta-analysis concluded that despite an
83% reduction in EOGBS incidence from IAP, IAP for
maternal GBS is not supported by conclusive evidence
due to a high risk of bias across RCTs [67]. Combining
this uncertainty with the results of this review makes it
increasingly difficult to ascertain whether the benefits of
administering IAP for EOGBS prevention outweigh the
harms to mothers and children. Large, well-designed
RCTs required to answer this question may no longer be
feasible as IAP is now the recommended treatment.
Instead, large, better quality, and longitudinal observa-
tional studies across countries with widespread IAP may
be an alternative to understand the adverse events oc-
curring in participants treated with IAP. Expanding
EOGBS prevention from risk-based strategies to univer-
sal antenatal screening introduces the risk of increasing
the number of low risk women treated with IAP. Up to
30% of mothers positive in pregnancy may become nega-
tive by birth, and less than 1% of mothers colonised in
labour have a baby with EOGBS, all of whom could be
unnecessarily exposed to potential harms [13, 7]. As
observational evidence on universal GBS screening
effectiveness is limited due to inherent biases [68, 9], an
RCT could inform on both the effectiveness and harms
of screening and IAP treatment for neonatal GBS disease
prevention.
Conclusions
The evidence on the adverse events from IAP treatment
for neonatal GBS disease prevention is unclear, incon-
sistent, and/or at risk of bias. There is consistent
evidence that GBS antibiotic prophylaxis alters the infant
microbiome, and some inconsistent evidence that IAP
increases antibiotic resistance. However, this evidence is
at risk of bias, and the clinical consequences of the
microbiome alterations are unknown. There is evidence
Seedat et al. BMC Pregnancy and Childbirth  (2017) 17:247 Page 12 of 14from a single long-term RCT associating IAP in pre-
term labour with potentially severe consequences such
as cerebral palsy, however, it has applicability concerns,
unclear biological plausibility, and was not replicated in
a similar RCT. These limitations preclude the drawing
of any accurate conclusions on the frequency of adverse
events from IAP treatment for neonatal GBS disease
prevention. Larger, better quality, and longer studies are
needed to provide estimates of adverse events from IAP
treatment for neonatal GBS disease prevention.
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